Table 6.2-1 Crystallization trials of the C2ABC-His6-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
C2ABC-His6
C2ABC-His6
3.48 mg/ml (4 °C) +Ca2+
x x x x x x x x x x x
C2ABC-His6
4 mg/ml (4 °C) x x x x x x x x x x x
C2ABC-His6
5 mg/ml (4 °C) x x x x x x x x x x x
C2ABC-His6
5 mg/ml (4 °C) Chelex
x x x x x x x x x x x
Table 6.2-2 Crystallization trials of the His6-C2AB-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
His6-C2AB 23.01 mg/ml (20 °C)
x x x x
His6-C2AB 23.01 mg/ml (4 °C)
x x x x
His6-C2AB 5 mg/ml (20 °C)
x x x x x x x x x x x
His6-C2AB
5 mg/ml (4 °C) x x x x x x x x x x x
Table 6.2-3 Crystallization trials of the GST-C2E-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
GST-C2E
Table 6.2-4 Crystallization trials of the GST-C2B-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
GST-C2B
GST-C2B
Table 6.2-5 Crystallization trials of the Strep-C2ABC-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
Strep-C2ABC
Table 6.2-6 Crystallization trials of the GST-C2F-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
GST-C2F
Table 6.2-7 Crystallization trials of the GST-C2C-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
GST-C2C 4.95 mg/ml (20 °C)
x x x x x x
GST-C2C 4.94 mg/ml (4 °C)
x x x x x x
Table 6.2-8 Crystallization trials of the GST-C2F-phos-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
GST-C2F phos 4 mg/ml (20 °C)
x x x x x x x
Table 6.2-9 Crystallization trials of the GST-C2F-D1N-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
GST-C2F-D1N 4 mg/ml (20 °C)
x x x x x x
GST-C2F-D1N
4 mg/ml (4 °C) x x x x x x
Table 6.2-10 Crystallization trials of the GST-C2F-D2,3N-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
GST-C2F-D2,3N 4 mg/ml (20 °C)
x x x x x x x x x x x
GST-C2F-D2,3N
4 mg/ml (4 °C) x x x x x x x x x x x
Table 6.2-11 Crystallization trials of the GST-C2F-D1,2,3N-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
GST-C2F-D1,2,3 N
4 mg/ml (20 °C)
x x x x x x x
GST-C2F-D1,2,3 N
4 mg/ml (4 °C)
x x x x x x x
GST-C2F-D1,2,3 N
4 mg/ml (4 °C)
x x x x x
Table 6.2-12 Crystallization trials of the GST-C2F-pga-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
GST-C2F-pga 2.77 mg/ml (20 °C)
x x x x
Table 6.2-13 Crystallization trials of the GST-C2F-E1804del-fragment of otoferlin. Eleven different crystallization screens were used. The different tested protein concentrations and temperatures are shown in the left column. X indicates that the named conditions were tested within the marked crystallization screen.
JB_1-2-4-5 JB_6-7-8-10 Ammoniumsulfate Morpheus JB nuc-Pro JCSG MIDAS MD1-59 MIDAS MD1-59 diluted Natrix HT PGA-LM HT 96 Pro Plex
GST-C2F -E1804del 2.4 mg/ml (20 °C)
x x x x
7 C URRICULUM VITAE
Sandra Meese
Georg-August-University Göttingen
Department for Molecular Structural Biology Justus-von-Liebig Weg 11
Göttingen, Germany
E-mail: smeese1@gwdg.de
Personal data
Date of birth: March 21st, 1986 Place of birth: Holzminden (Germany) Nationality: German
Scientific education
2011 – 2015 PhD program “basic biology program” at
Georg-August-University School of Science (GAUSS)
Doctoral thesis: “Biochemical studies of the synaptic protein otoferlin”; in the department for Molecular Structural Biology under the supervision of Prof. Dr. Ralf Ficner
2010 Diploma in Chemistry – Georg-August-University Göttingen
Diploma thesis: “Protein Interaktionsstudien mittels NMR”; in the department for NMR-based Structural Biology under the supervision of Prof. Dr. Christian Griesinger
2007 Vordiplom in Chemistry – Georg-August-University Göttingen 2005 Georg-August-University Göttingen
2005 Allgemeine Hochschulreife (Abitur) Georg-von-Langen Schule, Holzminden